Skip to main content
. 2003 Oct;1(4):309–326. doi: 10.3121/cmr.1.4.309

Figure 13.

Figure 13

Schema of the NSABP B-30 trial comparing the sequential administration of AC followed by docetaxel with the combination of doxorubicin(A)-docetaxel(T) and with the triple combination of doxorubicin(A)-docetaxel(T)-cyclophosphamide(C) in patients with node-positive breast cancer.